Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$264.4M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
714.73%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$528.3M
Q3 2024
Cash
Q3 2024
P/E
-1.609
Nov 29, 2024 EST
Free Cash Flow
-$257.2M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021
Revenue $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021
Revenue $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $66.18M $13.55M $3.564M
YoY Change 388.51% 280.11%
% of Gross Profit
Research & Development $355.9M $55.63M $38.23M
YoY Change 539.71% 45.52%
% of Gross Profit
Depreciation & Amortization $115.0K $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $422.1M $69.18M $41.79M
YoY Change 510.1% 65.52%
Operating Profit -$422.1M -$69.18M -$41.79M
YoY Change 510.1% 65.52%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense $40.85M $4.539M $0.00
YoY Change 799.89%
% of Operating Profit
Other Income/Expense, Net -$423.0K -$132.0K -$45.00K
YoY Change 220.45% 193.33%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$381.6M -$64.77M -$41.84M
YoY Change 489.21% 54.81%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$381.6M -$64.77M -$41.84M
YoY Change 489.21% 54.81%
Net Earnings / Revenue
Basic Earnings Per Share -$5.43 -$41.59 -$60.87
Diluted Earnings Per Share -$3.88 -$0.70 -$0.45

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $721.3M $314.6M $102.2M
YoY Change 129.27% 207.72%
Cash & Equivalents $218.1M $267.1M $102.2M
Short-Term Investments $503.2M $47.51M $0.00
Other Short-Term Assets $10.56M $1.056M $62.00K
YoY Change 900.28% 1603.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $736.6M $316.1M $102.3M
YoY Change 133.07% 208.95%
Property, Plant & Equipment $3.374M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.678M $3.859M $0.00
YoY Change -30.6%
Total Long-Term Assets $6.052M $3.859M $0.00
YoY Change 56.83%
Total Assets $742.7M $319.9M $102.3M
YoY Change
Accounts Payable $41.92M $5.947M $1.133M
YoY Change 604.89% 424.89%
Accrued Expenses $42.27M $9.954M $10.61M
YoY Change 324.64% -6.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $85.16M $15.90M $11.74M
YoY Change 435.56% 35.44%
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.194M $10.29M $0.00
YoY Change -88.4%
Total Long-Term Liabilities $1.194M $10.29M $0.00
YoY Change -88.4%
Total Liabilities $86.35M $26.19M $11.74M
YoY Change 229.69% 123.1%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding 70.25M shares 1.558M shares 687.4K shares
Diluted Shares Outstanding 70.25M shares 1.558M shares 687.4K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $425.38 Million

About ACELYRIN, Inc.

ACELYRIN, Inc. operates as a biopharma company. The company is headquartered in Agoura Hills, California and currently employs 130 full-time employees. The company went IPO on 2023-05-05. The firm is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The firm has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The firm is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.

Industry: Pharmaceutical Preparations Peers: 89bio, Inc. Astria Therapeutics, Inc. Cullinan Therapeutics, Inc. INTERCEPT PHARMACEUTICALS, INC. Olema Pharmaceuticals, Inc. Oric Pharmaceuticals, Inc. Tyra Biosciences, Inc. Zentalis Pharmaceuticals, Inc. Zymeworks Inc.